Navigation Links
Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors

DANBURY, Conn., June 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has been elected as a new member of its Board of Directors, effective June 10, 2008. Dr. Ginsberg is currently Chief Executive Officer of Diabetes Technology Consultants where he advises Fortune 500 companies in the field of diabetes.

"We are pleased to welcome Barry to our Board of Directors at such an important time for Biodel," stated Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Barry's diabetes expertise and experience as a seasoned advisor to commercial stage companies will provide invaluable insights and contributions to Biodel as we prepare to file VIAject(TM)'s New Drug Application by the end of 2008."

Dr. Ginsberg joins the Company's Board of Directors with over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. While a Professor of Medicine at the University of Iowa (1977-90), he was a Principal Investigator of the prestigious Diabetes Control and Complications Trial.

Biodel also announced that Albert Cha, M.D., Ph.D. will depart from the Company's Board of Directors. Dr. Cha, a Managing Partner of Vivo Ventures, joined the Company's Board of Directors in July 2006.

"Albert has been a valued source of counsel and he served our Company and its shareholders well during our transition from an early stage private company to a public company with a late stage Phase III product candidate. We thank him for his service and wish him well," stated Dr. Steiner.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at


SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
4. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
11. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
Post Your Comments:
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences ... today that Mr. Pierre Laurin , President and Chief ... at the upcoming Piper Jaffray 27 th Annual Healthcare ... on December 1-2, 2015. st , at ... one-on-one meetings throughout the day. The presentation will be available ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
Breaking Biology News(10 mins):